These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29679606)

  • 1. Regulatory pitfalls and opportunities when repurposing for inhalation therapy.
    Lyapustina S
    Adv Drug Deliv Rev; 2018 Aug; 133():57-65. PubMed ID: 29679606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design control considerations for biologic-device combination products.
    Anderson D; Liu R; Anand Subramony J; Cammack J
    Adv Drug Deliv Rev; 2017 Mar; 112():101-105. PubMed ID: 28088344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.
    Hernandez JJ; Pryszlak M; Smith L; Yanchus C; Kurji N; Shahani VM; Molinski SV
    Front Oncol; 2017; 7():273. PubMed ID: 29184849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory considerations and intellectual property rights of repurposed drugs.
    Afzaal H; Waseem T; Saeed A; Noori FA; Obaidullah ; Babar MM
    Prog Mol Biol Transl Sci; 2024; 205():357-375. PubMed ID: 38789186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug repurposing in rare diseases: Myths and reality.
    Fetro C; Scherman D
    Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The road to market implantable drug delivery systems: a review on US FDA's regulatory framework and quality control requirements.
    Al-Jawadi S; Capasso P; Sharma M
    Pharm Dev Technol; 2018 Dec; 23(10):953-963. PubMed ID: 30084277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-device combination products: regulatory landscape and market growth.
    Bayarri L
    Drugs Today (Barc); 2015 Aug; 51(8):505-13. PubMed ID: 26380388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic drug device combination products: Regulatory and scientific considerations.
    Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
    Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications.
    Murteira S; Millier A; Ghezaiel Z; Lamure M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers.
    Begley CG; Ashton M; Baell J; Bettess M; Brown MP; Carter B; Charman WN; Davis C; Fisher S; Frazer I; Gautam A; Jennings MP; Kearney P; Keeffe E; Kelly D; Lopez AF; McGuckin M; Parker MW; Rayner C; Roberts B; Rush JS; Sullivan M
    Sci Transl Med; 2021 Sep; 13(612):eabd5524. PubMed ID: 34550729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan.
    Mochizuki M; Maeda H
    Front Med Technol; 2024; 6():1461460. PubMed ID: 39166152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
    Cummings JL; Zhong K
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):161-5. PubMed ID: 24502586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.
    Newman SP
    Adv Drug Deliv Rev; 2018 Aug; 133():5-18. PubMed ID: 29653129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.